Core Insights - The company reported a revenue of 309 million yuan for the first three quarters of 2025, representing a year-on-year decline of 4.41% [1] - The net profit attributable to shareholders increased to 52 million yuan, showing a significant year-on-year growth of 152.81% [1] - Basic earnings per share reached 0.11 yuan, reflecting a year-on-year increase of 155% [1]

Core Viewpoint - Sai Sheng Pharmaceutical (300485.SZ) reported a year-on-year increase in operating revenue for Q3 2025, but a significant decline in net profit attributable to shareholders [1] Financial Performance - Operating revenue for Q3 2025 reached 112 million yuan, representing a year-on-year increase of 3.50% [1] - Net profit attributable to shareholders was 4.0733 million yuan, showing a year-on-year decrease of 41.41% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -12.8664 million yuan [1]

证券日报网讯 10月23日晚间，赛升药业发布公告称，公司于2025年10月22日召开第五届董事会第十次 会议及第五届监事会第十次会议，审议通过了《关于2025年前三季度全资子公司计提资产减值损失的议 案》。 （文章来源：证券日报） ...

Core Viewpoint - Beijing Saiseng Pharmaceutical Co., Ltd. announced the approval of amendments to its Articles of Association and related governance systems to enhance compliance and governance structure, ensuring alignment with regulatory requirements [1][2][3] Group 1: Articles of Association Revision - The revision of the Articles of Association is based on various laws and regulations, including the Company Law and Securities Law of the People's Republic of China, aimed at optimizing systems and ensuring effective alignment with the latest regulatory frameworks [2] - The proposed amendments will be submitted for approval at the company's second extraordinary general meeting of shareholders in 2025, with management authorized to handle subsequent registration matters [2] Group 2: Governance System Improvement - In addition to revising the Articles of Association, the company is also updating its governance-related systems to enhance operational standards and governance structure [3] - The revisions and new systems are intended to strengthen internal governance and provide a solid foundation for sustainable development, responding to regulatory requirements and improving decision-making efficiency and risk management capabilities [3]

Core Insights - The company reported a revenue of 112 million yuan for Q3 2025, representing a year-on-year increase of 3.50% [1] - The net profit attributable to shareholders decreased by 41.41% to 4.0733 million yuan in Q3 2025 [1] - Basic earnings per share for Q3 2025 stood at 0.01 yuan [1] Financial Performance - For the first three quarters of 2025, the company achieved a total revenue of 309 million yuan, which is a year-on-year decline of 4.41% [1] - The net profit attributable to shareholders for the first three quarters increased significantly by 152.81% to 51.8596 million yuan [1] - Basic earnings per share for the first three quarters were reported at 0.11 yuan [1]

Group 1 - The core point of the article is that Sai Sheng Pharmaceutical held its 10th meeting of the 5th Board of Directors on October 22, 2025, where the proposal for the "2025 Q3 Report" was approved [1] - For the year 2024, the revenue composition of Sai Sheng Pharmaceutical is 99.63% from the pharmaceutical manufacturing industry and 0.37% from other businesses [1] - As of the time of reporting, the market capitalization of Sai Sheng Pharmaceutical is 5.8 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have sold overseas licenses worth 80 billion USD this year [1] - There is a discussion on the hot secondary market for biopharmaceuticals, while the primary market is facing challenges in fundraising [1]

Company Performance - Sai Sheng Pharmaceutical reported a revenue of approximately 309 million yuan for the first three quarters of 2025, a year-on-year decrease of 4.41% [1] - The net profit attributable to shareholders was approximately 51.86 million yuan, reflecting a year-on-year increase of 152.81% [1] - Basic earnings per share increased to 0.11 yuan, marking a year-on-year growth of 155% [1] Market Context - As of the report date, Sai Sheng Pharmaceutical has a market capitalization of 5.8 billion yuan [2] - The Chinese innovative drug sector has seen significant overseas licensing sales, totaling 80 billion US dollars this year [2] - The secondary market for biopharmaceuticals is experiencing a surge, while the primary market is facing challenges in fundraising [2]

北京赛升药业股份有限公司对外担保管理制度 北京赛升药业股份有限公司 对外担保管理制度 第一章 总则 第一条 为了保护投资者的合法权益，规范北京赛升药业股份有限公司（以 下简称"公司"）的对外担保行为，有效防范公司对外担保风险，确保公司资产 安全，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国民法典》《深圳证券交易所创业板股票上市规则》（以下简称"《创业 板上市规则》"）、《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》《上市公司监管指引第 8 号——上市公司资金往来、对外担 保的监管要求》等法律、法规、规范性文件以及《北京赛升药业股份有限公司章 程》(以下简称"《公司章程》")的有关规定，结合公司的实际情况，特制订本 制度。 第七条 公司为他人提供担保，应当采取反担保等必要的措施防范风险，反 担保应具有可执行力，反担保的提供方应具备实际承担能力。 第八条 公司独立董事应在年度报告中，对公司累计和当期对外担保情况做 出专项说明。 第二章 对外担保对象的审查 第九条 公司可以为具有独立法人资格并具有以下条件之一的单位提供担 1 北京赛升药业股份有限公司对外担 ...

北京赛升药业股份有限公司募集资金管理制度 北京赛升药业股份有限公司 募集资金管理制度 第一章 总则 第一条 为规范北京赛升药业股份有限公司（以下简称"公司"）募集资 金的存放、使用和管理，保证募集资金的安全，最大限度地保障投资者的合法 权益，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《深圳证券交易所创业板 股票上市规则》（以下简称"《创业板上市规则》"）、《上市公司监管指引 第 2 号——上市公司募集资金管理和使用的监管要求》《深圳证券交易所上市 公司自律监管指引第 2 号——创业板上市公司规范运作》等法律、法规和规范 性文件和《北京赛升药业股份有限公司章程》（以下简称"《公司章程》"） 的规定并结合公司实际情况，特制订本制度。 第二条 本制度所称募集资金，是指公司通过发行股票或者其他具有股权 性质的证券，向投资者募集并用于特定用途的资金，不包括公司为实施股权激 励计划募集的资金。 第三条 发行股票、可转换债券或其他证券的募集资金到位后，公司应及 时办理验资手续，由具有证券从业资格的会计师事务所出具验资报告。 第四条 募集资金只能用于公司在发 ...

北京赛升药业股份有限公司董事会审计委员会工作细则 北京赛升药业股份有限公司 董事会审计委员会工作细则 第一章 总则 第一条 为强化董事会决策功能，做到事前审计、专业审计，确保董事会对 经理层的有效监督，完善北京赛升药业股份有限公司（以下简称"公司"）治理 结构，根据《中华人民共和国公司法》《上市公司治理准则》《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》（以下简称"《规范运 作指引》"）、《北京赛升药业股份有限公司章程》（以下简称"《公司章程》"）及其 他有关规定，公司特设立董事会审计委员会（以下简称"审计委员会"），并制定 本细则。 第二条 董事会审计委员会是董事会下设的专门工作机构，主要负责公司内、 外部审计的沟通、监督和核查工作，并行使《中华人民共和国公司法》规定的监 事会的职权。 第二章 人员组成 第三条 审计委员会成员由 3 名董事组成，非独立董事 1 名，应当为不在公 司担任高级管理人员的董事，独立董事 2 名，其中至少有一名独立董事为专业会 计人士。董事会成员中的职工代表可以成为审计委员会成员。 第四条 审计委员会委员由董事长、二分之一以上独立董事或者全体董事三 分 ...